Femoral Geometry in Bisphosphonate-related Atypical Femoral Fracture and Bisphosphonate-naïve Atypical Femoral Fracture
DOI:
https://doi.org/10.56929/jseaortho-2025-0234Keywords:
Postmenopausal osteoporosis, atypical femoral fracture, femoral geometry, Bisphosphonate-related AFF, Bisphosphonate-naïve AFFAbstract
Purpose: To compare the radiographic characteristics of femoral geometry between bisphosphonate-related atypical femoral fracture (BPAFF) and bisphosphonate-naïve atypical femoral fracture (BPnAFF).
Methods: A case-control study was conducted at the Police General hospital in Bangkok, Thailand, from January 2012 to December 2023; medical records and all available radiographs of hip and femoral fractures were reviewed. Atypical femoral fractures (AFF) were defined using the American Society for Bone and Mineral Research (ASBMR) 2013 criteria. BPAFF was identified in patients with a documented history of bisphosphonate prescription. The analysis encompassed a comparative assessment of femoral geometry parameters, including femoral offset, neck shaft angle, and lateral cortical thickness index (LCTi), between individuals with BPAFF and BPnAFF.
Results: A total of 13 BPAFFs and 10 BPnAFFs were identified in 19 patients. The prevalence rate in our hospital was 1.69%. Patients with BPAFF were comparatively younger (73.46±6.30 vs. 82.6±3.71 years, p<0.001). Fractures were more prevalent in the subtrochanteric region in the BPAFF group (10 [76.92%] vs. 3 [30%], p=0.04). BPAFF group had significantly higher LCTi at both subtrochanteric region (0.258±0.050 vs 0.211±0.067, p=0.037), and the femoral shaft level (0.357±0.056 vs 0.288±0.059, p=0.005). However, no statistically significant differences were observed in other femoral geometry parameters between both groups.
Conclusions: BPAFF exhibited a higher LCTi at the subtrochanteric and femoral shaft levels than BPnAFFs. On average, patients with BPAFF were younger than those with BPnAFF. Most BPAFF cases occurred in the subtrochanteric region, whereas BPnAFF cases were more commonly located in the diaphysis.
Metrics
References
Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2013;29:1-23.
Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 2015;86:100-7.
Black DM, Abrahamsen B, Bouxsein ML, et al. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 2018;40:333-68.
Szolomayer LK, Ibe IK, Lindskog DM. Bilateral atypical femur fractures without bisphosphonate exposure. Skeletal Radiol 2017;46:241-7.
Georgiadis GF, Begkas DG, Maniatis KA, et al. Atypical femoral fracture in a patient without bisphosphonate or denosumab exposure - A case report. J Orthop Case Rep 2021;11:21-4.
Oh Y, Wakabayashi Y, Kurosa Y, et al. Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: Mechanical analysis by the CT-based finite element method. Injury 2014;45:1764-71.
Mahjoub Z, Jean S, Leclerc J-T, et al. Incidence and characteristics of atypical femoral fractures: Clinical and geometrical data. J Bone Miner Res 2016;31:767-76.
Kumar S, Chang R, Reyes M, et al. Atypical femoral fracture in a bisphosphonate-naïve patient on denosumab for osteoporosis. Arch Osteoporos 2022;17:131.
Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 2016;11:25.
Napoli N, Schwartz AV, Palermo L, et al. Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fractures. J Clin Endocrinol Metab 2013;98:659-67.
Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis. Clin Orthop Relat Res 2016;474:1886-93.
Lim SJ, Yeo I, Yoon PW, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporos Int 2018;29:2427-35.
Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363-74.
Saita Y, Ishijima M, Mogami A, et al. The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 2014;33:311-8.
Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37.
Thompson RN, Phillips JRA, McCauley SHJ, et al. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012;94:385-90.
Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50.
Allen MR, Iwata K, Phipps R, et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006;39:872-9.
Norman TL, Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 1997;20:375-9.
Luangkittikong S, Unnanuntana A. Prevalence of atypical femoral fractures in Thai patients at a single institution. J Med Assoc Thai 2014;97:635-43.
Lee SH, Lee YH, Suh J-S. Lateral cortical thickening and bone heterogeneity of the subtrochanteric femur measured with quantitative CT as indicators for early detection of atypical femoral fractures in long-term bisphosphonate users. Am J Roentgenol 2017;209:867-73.
Koeppen VA, Schilcher J, Aspenberg P. Atypical fractures do not have a thicker cortex. Osteoporos Int 2012;23:2893-6.
Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-62.
Taormina DP, Marcano AI, Karia R, et al. Symptomatic atypical femoral fractures are related to underlying hip geometry. Bone 2014;63:1-6.
van der Meulen MCH, Boskey AL. Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther 2012;14:220.
Severyns M, Belaid D, Aubert K, et al. Biomechanical analysis of the correlation between mid-shaft atypical femoral fracture (AFF) and axial varus deformation. J Orthop Surg Res 2022;17:165.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Royal College of Orthopaedic Surgeons of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
